LIFECORE BIOMEDICAL, INC. Long-term Line of Credit, Noncurrent
LIFECORE BIOMEDICAL, INC. (LFCR) had Long-term Line of Credit, Noncurrent of $8.50 million as of 2024-11-24, per its 10-Q filed 2025-01-02.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation › Long-Term Debt, Excluding Current Maturities
us-gaap:LongTermLineOfCredit · last filed 2025-01-02
- 2024-11-24: Long-term Line of Credit, Noncurrent $8.50M.
- 2024-08-25: Long-term Line of Credit, Noncurrent $21.61M.
- 2024-05-26: Long-term Line of Credit, Noncurrent $19.69M.
- 2024-02-25: Long-term Line of Credit, Noncurrent $19.91M.
| Period end | Long-term Line of Credit, Noncurrent |
|---|---|
| 2024-11-24 | $8.50M 10-Q · filed 2025-01-02 |
| 2024-08-25 | $21.61M 10-Q · filed 2024-10-04 |
| 2024-05-26 | $19.69M 10-Q · filed 2025-01-02 |
| 2024-02-25 | $19.91M 10-Q · filed 2024-08-09 |
| 2023-11-26 | $16.88M 10-Q · filed 2024-08-09 |
| 2023-08-27 | $19.09M 10-Q · filed 2024-08-09 |
| 2023-05-28 | $16.81M 10-K · filed 2024-08-26 |
| 2023-02-26 | $16.00M 10-K · filed 2024-03-20 |
| 2022-05-29 | $0.00 10-K · filed 2024-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |